Hippocratic AI has acquired Grove AI, a company specializing in agentic AI for pharmaceutical research and clinical trial operations. The acquisition brings together two organizations focused on expanding access, accelerating research, and reducing friction across the life sciences value chain. Grove AI has supported more than 10 million patient interactions over the past year for complex research and development workflows, including work with two of the top five global pharmaceutical companies.
Joining Hippocratic AI will enable Grove AI to reduce manual bottlenecks and improve AI-driven operations, while continuing to adhere to responsible, high-trust agentic AI standards in the life sciences industry. Grove AI expressed appreciation to its customers and partners for trusting the company with critical processes and acknowledged the commitment of its employees, investors, and advisors in making the acquisition milestone possible.
As part of Hippocratic AI, Grove AI will continue delivering enterprise-grade solutions to the life sciences industry, now supported by the scale and technology of its new parent company. The combined organization aims to raise standards for AI-driven processes in pharmaceutical research and clinical trials, improving efficiency while ensuring reliability and trust in patient-facing applications. With the acquisition, Hippocratic AI strengthens its ability to support life sciences enterprises and optimize complex workflows across the sector.
